PCTC
CRSP icon

Perkins Coie Trust Company’s CRISPR Therapeutics CRSP Stock Holding History

Perkins Coie Trust Company’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-200
Closed -$6.8K – 330
2025
Q1 		$6.8K Hold
200
– – ﹤0.01% 256
2024
Q4 		$7.87K Hold
200
– – ﹤0.01% 245
2024
Q3 		$9.39K Hold
200
– – ﹤0.01% 248
2024
Q2 		$10.8K Hold
200
– – ﹤0.01% 232
2024
Q1 		$13.6K Hold
200
– – ﹤0.01% 196
2023
Q4 		$12.5K Buy
+200
New +$11.1K ﹤0.01% 202

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perkins Coie Trust Company's CRSP Position: Q2 2025 in Review

Perkins Coie Trust Company sold out of CRISPR Therapeutics (CRSP) in Q2 2025, closing a stake of 200 shares — an estimated $6.8K sold.

Perkins Coie Trust Company first reported a position in CRSP in Q4 2023 and held it in 6 quarters. The position peaked at $13.6K in Q1 2024. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

  • Perkins Coie Trust Company reported no remaining CRISPR Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Perkins Coie Trust Company sold 200 CRISPR Therapeutics shares in Q2 2025, an estimated $6.8K.
  • Perkins Coie Trust Company first reported a position in CRISPR Therapeutics in Q4 2023 and held it in 6 quarters.
  • Perkins Coie Trust Company's CRISPR Therapeutics position peaked at $13.6K in Q1 2024.
  • 433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on Perkins Coie Trust Company's 13F filing for Q2 2025, filed 10 Jul 2025.